- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis，MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
- Interventions
- Not listed
- Lead sponsor
- MPN Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2329–2352
of 7,258
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- pharmacological study, tacrolimus, sirolimus, anti-thymocyte globulin, fludarabine phosphate, busulfan, bortezomib, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
- Other · Drug · Biological + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Open Posterior Thoracolumbar Spinal Fusion Procedure
- Interventions
- Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Body Composition, Performance Measures, Hormone Profiles, Blood Lipid Profiles
- Interventions
- Shroom Tech Sport, Placebo
- Dietary Supplement
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- Asperger Syndrome, High Functioning Autism
- Interventions
- PVGS
- Behavioral
- Lead sponsor
- Minna Levine, PhD
- Industry
- Eligibility
- 11 Years to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, goserelin acetate, assessment of therapy complications, quality-of-life assessment, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure; With Decompensation, Lower Extremity Edema, Heart Failure，Congestive
- Interventions
- Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.
- Other
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, sargramostim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, etoposide phosphate, ifosfamide, isotretinoin, melphalan, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Portland, Oregon + 4 more
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Standard Adjuvant Endocrine Therapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 162
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more
- Conditions
- Type 2 Diabetes
- Interventions
- Whole Fruit
- Other
- Lead sponsor
- Harvard School of Public Health (HSPH)
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
- Conditions
- Healthy
- Interventions
- High-sodium diet 300 mmol sodium/day, Low-sodium diet 10 mmol sodium/day
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Healthy
- Interventions
- Multimodal High-Intensity Interval Training Intervention
- Other
- Lead sponsor
- Oakland University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Michigan
- Conditions
- African Americans With Hypertension.
- Interventions
- 12-week lifestyle modification
- Behavioral
- Lead sponsor
- Morehouse School of Medicine
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 1259
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
- Conditions
- Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
- Interventions
- VIP943 (QW), VIP943 (BIW)
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Cincinnati, Ohio • Nashville, Tennessee + 2 more
- Conditions
- Prostate Cancer, Prostatic Neoplasms
- Interventions
- 64Cu-SAR-bisPSMA
- Drug
- Lead sponsor
- Clarity Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
- Conditions
- Breast Cancer, Tear, Breast Cancer Female
- Interventions
- Schirmer Strip
- Other
- Lead sponsor
- Namida Lab
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Cladribine, Cyclosporine, Cytarabine, Filgrastim, Fludarabine Phosphate, Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan, Mitoxantrone Hydrochloride, Mycophenolate Mofetil, Questionnaire Administration, Sirolimus, Total-Body Irradiation, Melphalan Hydrochloride
- Drug · Biological · Procedure + 2 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
- Interventions
- CyberKnife SBRT
- Radiation
- Lead sponsor
- Crozer-Keystone Health System
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- IL-2 Induced Hypotension
- Interventions
- M40403
- Drug
- Lead sponsor
- MetaPhore Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Portland, Oregon • Salt Lake City, Utah
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Interventions
- Azacitidine, Pevonedistat
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
- Conditions
- AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Interventions
- Anoscopy, Biospecimen Collection, Capecitabine, Colonoscopy, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Lymph Node Biopsy, Magnetic Resonance Imaging, Mitomycin, Nivolumab, Positron Emission Tomography, Proctoscopy, Questionnaire Administration, Sigmoidoscopy
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 14
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more